Request TOC and Sample - Disease-Modifying Agents Market by Drug Class (Interferon Beta-1?/?, Natalizumab, Mitoxantrone, Glatiramer Acetate, Fingolimod, Dimethyl Fumarate, Ocrelizumab, Teriflunomide, Ciclosporin, Cyclophosphamide, Hydroxychloroquine, Leflunomide, Methotrexate, Mycophenolate, Sulfasalazine, Others), by Indication (Multiple Sclerosis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Systemic Sclerosis, Cancer, Others), by Therapy Type (Monotherapy, Combination therapy), by Route of Administration (Oral, Infusion, Subcutaneous, Intravenous) and by End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Disease-Modifying Agents Market, by Drug Class (Interferon Beta-1?/?, Natalizumab, Mitoxantrone, Glatiramer Acetate, Fingolimod, Dimethyl Fumarate, Ocrelizumab, Teriflunomide, Ciclosporin, Cyclophosphamide, Hydroxychloroquine, Leflunomide, Methotrexate, Mycophenolate, Sulfasalazine, Others), by Indication (Multiple Sclerosis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Systemic Sclerosis, Cancer, Others), by Therapy Type (Monotherapy, Combination therapy), by Route of Administration (Oral, Infusion, Subcutaneous, Intravenous) and, by End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032